On July 25, 2022, InventisBio Co., Ltd. (InventisBio; Stock Code: 688382) listed on the STAR Market of the Shanghai Stock Exchange. InventisBio adopted the fifth set of listing standard for the STAR market, publicly offered 115,000,000 common shares at an issue price of RMB 18.12 per share and raised a total amount of RMB 2. 0838 billion.
Founded in 2013, InventisBio is an innovative drug research and development enterprise, focusing on the R&D of innovative drugs for major diseases such as cancer and metabolic diseases. InventisBio's product pipeline includes three core products in clinical trials and five preclinical research projects. All three core products have been approved for phase II or III clinical trials, and the R&D progress of these products is world-leading.
JunHe has been the legal advisor of InventisBio since 2016, and has provided one-stop legal services for it with respect to private placement, capital market, intellectual properties, pharmaceutical compliance and dispute resolution. This includes: (a) as the financing lawyer, JunHe assisted the company to complete Round A to Round D private placement, participated in the design of the transaction structure (including the setup and dismantling of the red chip structure), the drafting and negotiation of transaction documents, the contract signing, the project closing and other matters; (2) As the IPO issuer’s lawyer, JunHe assisted InventisBio in restructuring to establish a joint stock company, formulated employee equity incentive plans, issued legal opinions and the whole set of notification documents for the IPO legal matters, assisted the company to complete the pre-listing tutoring, the acceptance inspection, and the IPO notification, reviewed the meeting of the IPO committee, and replied to feedback from the Shanghai Stock Exchange and the China Securities Regulatory Commission; (3) As the PRC and US patent advisor, JunHe issued an IP DD Report; (4) As the patent litigation agent, JunHe represented the company in patent litigation;（5）As the Hong Kong legal advisor, JunHe issued opinions on Hong Kong law for the establishment and existing of InventisBio’s shareholders;（6）As the perennial legal counsel, JunHe advised on pharmaceutical compliance, daily operations, trademarks and other matters.
Partner LI, Chenliang led the JunHe team for InventisBio’s IPO on the STAR market, its private placement and provided perennial legal counsel service. Partner NIU, Yuandong led the JunHe team for the IPO on the STAR market.
Partner WANG, Zhaohui (Zoe) led the JunHe team for patent legal service and partner YE, Yurong led JunHe’s Hong Kong team in providing legal service.